0
Locally Advanced Breast Cancer:
          Radiotherapy

     Rob Dinniwell, MD
     Radiation Medicine Program
     Prince...
Outline
1. Individual Patient
2. Anatomy:
  Target Volume Delineation
  Organs at Risk
3. Response Assessment and Adaptive...
Outline
1. Individual Patient
   52 year old woman
   presents with: thickening in Rt breast
   managed initially with a n...
•
                  FUTURE
    Improved imaging ⇒ validation

• Modulation of therapeutic intensity based on maps
  diseas...
Outline
1. Individual Patient
   cT4N1M0 Rt breast ca
   ER/PR –ve, Her2/NEU +ve
   Neoadjuvant Chemotherapy AC ->
   Taxo...
3-dimensional Volume
   Rendering of a Pre-
        Treatment CT
      Simulation Data
                  set:
   Anterior ...
3-dimensional Volume
   Rendering of a Pre-
        Treatment CT
      Simulation Data
                  set:
   Anterior ...
3-dimensional Volume
   Rendering of a Pre-
        Treatment CT
      Simulation Data
                  set:
      Axial ...
3-dimensional Volume
     Rendering of a Pre-
           Treatment CT
        Simulation Data
                    set:
Axi...
3-dimensional Volume
       Rendering of a
    Post-Treatment CT
      Simulation Data
                  set:
   Anterior ...
3-dimensional Volume
       Rendering of a
    Post-Treatment CT
      Simulation Data
                  set:
   Anterior ...
Pre-Treament:
         Axial




Post-Treatment
          Axial
Outline
1. Individual Patient
2. Anatomy:
  Target Volume Delineation
  Organs at Risk
3. Response Assessment and Adaptive...
Outline
1. Individual Patient
2. Anatomy:
  Target Volume Delineation
     Regional Lymphatics
Visible Human Dataset
The Visible Human Male data set, axial images with pixel
heights and widths of 0.14 mm and 1 mm axia...
High resolution thoracic axial section from the Visible Human Anatomic Series
Relationship of adjacent lymph nodes (green ...
Outline
1. Individual Patient
2. Anatomy:
  Target Volume Delineation
  Organs at Risk
     Brachial plexus
Radiation-induced brachial plexopathy
Radiation-induced brachial plexopathy




          Galecki, Acta Oncologica 2006
Brachial Plexus
• Phased array torso coil
• Coronal STIR sequence
• Oblique sagittal STIR with slice orientation
  perpend...
Raphael, Anesthesiology 2005
Outline
1. Individual Patient
2. Anatomy:
  Target Volume Delineation
  Organs at Risk
     Cone Beam CT
Outline
1. Individual Patient
2. Anatomy:
  Target Volume Delineation
  Organs at Risk
3. Response Assessment and Adaptive...
Goal
To develop standardized imaging techniques
that can non-invasively monitor response

To quantify changes in size and ...
Dynamic Contrast-Enhanced
        (DCE) MRI
delineate architectural and dynamic features
of breast tumors and determine th...
Dynamic Contrast-Enhanced
           (DCE) MRI
Tumor angiogenesis results in:
• formation of blood microvessels excessivel...
Dynamic Contrast-Enhanced
           (DCE) MRI
Tumor angiogenesis results in:
• formation of blood microvessels excessivel...
Pre-




Post-




        Changes can be quantified by analyzing enhancement parameters of
        dynamic contrast-enhan...
Dynamic Contrast-Enhanced
        (DCE) MRI
• Imaging at Weeks:
  0, 1, 4, 8, and pre-operatively
• GE 1.5-tesla MR scanne...
Outline
1. Individual Patient
2. Anatomy:
  Target Volume Delineation
  Organs at Risk
3. Response Assessment and Adaptive...
Postmastectomy radiotherapy
• A portion of patients remain at risk for local
  recurrence following surgery

• In those at...
Oxford Overview
•   Mastectomy +/- Postmastectomy Radiotherapy




                                  Local Recurrence

   ...
Oxford Overview
•   Mastectomy +/- Postmastectomy Radiotherapy




                                     Survival

        ...
Local-Regional Recurrence
     and Pathological Extent of
              Disease
• MD Anderson experience

• Mastectomy, ch...
Pathological Size of Primary
           Tumor
       50%
       45%
       40%
       35%
5-Year
  LRR 30%
       25%     ...
Pathological Nodal Status
      60%

      50%

5-Year 40%
  LRR
       30%                                  Adjuvant
    ...
Local-Regional Recurrence Risk
 After Preoperative Chemotherapy
          and Mastectomy
• MD Anderson experience

• 150 p...
Factors Associated with Local-
     Regional Recurrence
     Pretreatment Factors
     • Clinical stage
     • Clinical T ...
Postmastectomy Radiotherapy
     Following Neoadjuvant
         Chemotherapy
• MD Anderson experience
• 676 patients treat...
Comparison Between Groups

                                                             •       Irradiated patients
      ...
Rate of Local-Regional Recurrence




                              No XRT

                              XRT




        ...
Local-Regional Recurrence
Clinical Stage III to IV > pCR




                              No XRT


                      ...
Local-Regional Recurrences in
     Patients with a pCR
                            93%      n=62


                       ...
Patients with Stage III Disease
          and a pCR
                                         88%




                     ...
Patients with Stage III Disease
          and a pCR

                                         77%




                    ...
Post mastectomy radiotherapy in
    Patients <35 Years with Stage II-III

• MD Anderson experience

• 107 patients <35 yea...
Post mastectomy radiotherapy in
    Patients <35 Years with Stage II-III

• 80 PMRT vs 27 no PMRT
• PMRT group showed:
  –...
Determining and Individualizing
Radiotherapy Treatment Fields
A majority of women receiving
neoadjuvant chemotherapy have a
 downstaging of their pathology.

      The use of the remai...
Controversies
• A conservative (but aggressive) approach would be to
  recommend radiation to all LABC patients
• However,...
Radiation
•   At least four metastatic lymph nodes or 5 cm of residual
    disease in the breast after chemotherapy clearl...
Outline
1. Individual Patient
2. Anatomy:
  Target Volume Delineation
  Organs at Risk
3. Response Assessment and Adaptive...
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
RADIOTHERAPY FOR BREAST CANCER
Upcoming SlideShare
Loading in...5
×

RADIOTHERAPY FOR BREAST CANCER

3,096

Published on

Published in: Health & Medicine
1 Comment
4 Likes
Statistics
Notes
  • Congratulations !!! .. Feel free to join us. Thank you in advance for your participation and sharing your 'favorites'. .. With friendship from France. Bernard
    'GREAT CAUSES and JUST CAUSES' Slideshare group http://www.slideshare.net/group/great-causes-and-just-causes
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total Views
3,096
On Slideshare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
305
Comments
1
Likes
4
Embeds 0
No embeds

No notes for slide

Transcript of "RADIOTHERAPY FOR BREAST CANCER"

  1. 1. Locally Advanced Breast Cancer: Radiotherapy Rob Dinniwell, MD Radiation Medicine Program Princess Margaret Hospital, University of Toronto, Canada
  2. 2. Outline 1. Individual Patient 2. Anatomy: Target Volume Delineation Organs at Risk 3. Response Assessment and Adaptive Radiotherapy 4. Conclusion: Integration into treatment delivery 5. Questions
  3. 3. Outline 1. Individual Patient 52 year old woman presents with: thickening in Rt breast managed initially with a naturopath progressed to mass encompassing entire breast and associated lymphadenopathy
  4. 4. • FUTURE Improved imaging ⇒ validation • Modulation of therapeutic intensity based on maps disease burden / biology • Large robust clinical trials (RCT) • Further improve techniques for streamlined integration of diagnostic MRI with diagnostic and therapeutic local interventions
  5. 5. Outline 1. Individual Patient cT4N1M0 Rt breast ca ER/PR –ve, Her2/NEU +ve Neoadjuvant Chemotherapy AC -> Taxotere with Herceptin Reaction during administration of 2nd cycle
  6. 6. 3-dimensional Volume Rendering of a Pre- Treatment CT Simulation Data set: Anterior Projection
  7. 7. 3-dimensional Volume Rendering of a Pre- Treatment CT Simulation Data set: Anterior Projection
  8. 8. 3-dimensional Volume Rendering of a Pre- Treatment CT Simulation Data set: Axial Projection
  9. 9. 3-dimensional Volume Rendering of a Pre- Treatment CT Simulation Data set: Axial Oblique Projection
  10. 10. 3-dimensional Volume Rendering of a Post-Treatment CT Simulation Data set: Anterior Projection
  11. 11. 3-dimensional Volume Rendering of a Post-Treatment CT Simulation Data set: Anterior Projection
  12. 12. Pre-Treament: Axial Post-Treatment Axial
  13. 13. Outline 1. Individual Patient 2. Anatomy: Target Volume Delineation Organs at Risk 3. Response Assessment and Adaptive Radiotherapy 4. Integration into treatment delivery 5. Conclusion
  14. 14. Outline 1. Individual Patient 2. Anatomy: Target Volume Delineation Regional Lymphatics
  15. 15. Visible Human Dataset The Visible Human Male data set, axial images with pixel heights and widths of 0.14 mm and 1 mm axial slice spacing, and the Female data set, pixels measuring 0.33 mm x 0.33mm with 0.33 mm axial slice spacing, were obtained from National Institute of Health. The anatomical images of the Visible Human datasets consist of high-resolution axial sections and provide a useful reference.
  16. 16. High resolution thoracic axial section from the Visible Human Anatomic Series Relationship of adjacent lymph nodes (green arrow) to the adjacent vessels (red arrow).
  17. 17. Outline 1. Individual Patient 2. Anatomy: Target Volume Delineation Organs at Risk Brachial plexus
  18. 18. Radiation-induced brachial plexopathy
  19. 19. Radiation-induced brachial plexopathy Galecki, Acta Oncologica 2006
  20. 20. Brachial Plexus • Phased array torso coil • Coronal STIR sequence • Oblique sagittal STIR with slice orientation perpendicular to long axis of brachial plexus • Oblique sagittal T1 • 20 subjects
  21. 21. Raphael, Anesthesiology 2005
  22. 22. Outline 1. Individual Patient 2. Anatomy: Target Volume Delineation Organs at Risk Cone Beam CT
  23. 23. Outline 1. Individual Patient 2. Anatomy: Target Volume Delineation Organs at Risk 3. Response Assessment and Adaptive Radiotherapy Magnetic Resonance Imaging
  24. 24. Goal To develop standardized imaging techniques that can non-invasively monitor response To quantify changes in size and spread, as well as track specific biologic and physiologic markers of malignancy To help predict response to therapy and facilitate patient specific treatment
  25. 25. Dynamic Contrast-Enhanced (DCE) MRI delineate architectural and dynamic features of breast tumors and determine their size develop standardized imaging techniques that can non-invasively monitor response (DCE) MRI can provide information regarding pathophysiologic response of tumor vasculature
  26. 26. Dynamic Contrast-Enhanced (DCE) MRI Tumor angiogenesis results in: • formation of blood microvessels excessively permeable and enhanced leakage of bloodborne contrast agents • augmented contrast enhancement Therapeutic response: • tumor angiogenesis halted • development of necrosis and fibrosis • establishment of a microcapillary network with properties different from that feeding the growing tumor Changes can be quantified by analyzing enhancement parameters of dynamic contrast-enhanced images
  27. 27. Dynamic Contrast-Enhanced (DCE) MRI Tumor angiogenesis results in: • formation of blood microvessels excessively permeable and enhanced leakage of bloodborne contrast agents • augmented contrast enhancement Therapeutic response: • tumor angiogenesis halted • development of necrosis and fibrosis • establishment of a microcapillary network with properties different from that feeding the growing tumor
  28. 28. Pre- Post- Changes can be quantified by analyzing enhancement parameters of dynamic contrast-enhanced images Chou, Acad Radiol 2007
  29. 29. Dynamic Contrast-Enhanced (DCE) MRI • Imaging at Weeks: 0, 1, 4, 8, and pre-operatively • GE 1.5-tesla MR scanner • 4 channel breast coil • Spoiled Gradient Recalled Sequence (SPGR) • Intravenous Gd-DTPA • Tumor size and modelling • 10 subjects
  30. 30. Outline 1. Individual Patient 2. Anatomy: Target Volume Delineation Organs at Risk 3. Response Assessment and Adaptive Radiotherapy 4. Conclusion: Integration into treatment delivery 5. Questions
  31. 31. Postmastectomy radiotherapy • A portion of patients remain at risk for local recurrence following surgery • In those at risk, radiotherapy can: – Reduce local regional recurrence – Increase cause specific and overall survival
  32. 32. Oxford Overview • Mastectomy +/- Postmastectomy Radiotherapy Local Recurrence • 72% decrease Lancet 366:2087, 2005
  33. 33. Oxford Overview • Mastectomy +/- Postmastectomy Radiotherapy Survival • 5% for those with +ve LN’s Lancet 366:2087, 2005
  34. 34. Local-Regional Recurrence and Pathological Extent of Disease • MD Anderson experience • Mastectomy, chemotherapy and no radiation – 150 patients preoperative chemotherapy – 1031 patients postoperative chemotherapy Buchholz et al., Int J Radiat Oncol Biol Phys, 2003
  35. 35. Pathological Size of Primary Tumor 50% 45% 40% 35% 5-Year LRR 30% 25% Adjuvant 20% Preop 15% 10% 5% 0% 0-2.0 cm 2.1-5.0 cm >5.0 cm
  36. 36. Pathological Nodal Status 60% 50% 5-Year 40% LRR 30% Adjuvant Preop 20% 10% 0% 0 LN+ 1-3 LN+ 4 or > LN+
  37. 37. Local-Regional Recurrence Risk After Preoperative Chemotherapy and Mastectomy • MD Anderson experience • 150 patients, 1974 to 1998 – Preoperative chemotherapy administered – Modified radical mastectomy performed – NO radiotherapy Buchholz et al., JCO, 2002
  38. 38. Factors Associated with Local- Regional Recurrence Pretreatment Factors • Clinical stage • Clinical T and N stage Postoperative Factors • Number of + LNs • Primary tumor size Buchholz et al., JCO, 2002
  39. 39. Postmastectomy Radiotherapy Following Neoadjuvant Chemotherapy • MD Anderson experience • 676 patients treated with neoadjuvant chemotherapy • Mastectomy • 134 patients NO radiotherapy • 542 patients radiotherapy Huang et al., JCO, 2004
  40. 40. Comparison Between Groups • Irradiated patients worse ns gi ar M /+ s No Radiotherapy LN se lo > Radiotherapy C or e 4 ns po es .R 3 2- in cN M 4 3- cT 0 200 400 600 Percentage of Patients Huang et al., JCO, 2004
  41. 41. Rate of Local-Regional Recurrence No XRT XRT Huang et al., JCO, 2004
  42. 42. Local-Regional Recurrence Clinical Stage III to IV > pCR No XRT XRT Huang et al., JCO, 2004
  43. 43. Local-Regional Recurrences in Patients with a pCR 93% n=62 67% n=12 Clinical Stage III Disease McGuire et al., Int J Radiat Oncol Biol Phys, 2007 Jul 15;68(4):1004-9. Epub 2007 Apr 6.
  44. 44. Patients with Stage III Disease and a pCR 88% 41% McGuire et al., Int J Radiat Oncol Biol Phys, 2007 Jul 15;68(4):1004-9.
  45. 45. Patients with Stage III Disease and a pCR 77% 33% McGuire et al., Int J Radiat Oncol Biol Phys, 2007 Jul 15;68(4):1004-9.
  46. 46. Post mastectomy radiotherapy in Patients <35 Years with Stage II-III • MD Anderson experience • 107 patients <35 years of age with IIA-IIIC – Treated with doxorubicin based preoperative chemotherapy – Modified radical mastectomy performed – +/- radiotherapy Garg et al., Int J Radiat Oncol Biol Phys, 2007 Sep 12; [Epub ahead of print]
  47. 47. Post mastectomy radiotherapy in Patients <35 Years with Stage II-III • 80 PMRT vs 27 no PMRT • PMRT group showed: – Better LRC (88% vs 63% at 5 years) – Better OS (67% vs 48% at 5 years) • “benefit seen for PMRT in young patients provides valuable data to better tailor adjuvant, age-specific treatment decisions” Garg et al., Int J Radiat Oncol Biol Phys, 2007 Sep 12; [Epub ahead of print]
  48. 48. Determining and Individualizing Radiotherapy Treatment Fields
  49. 49. A majority of women receiving neoadjuvant chemotherapy have a downstaging of their pathology. The use of the remaining pathological extent of disease alone to determine the likelihood of local regional recurrence is not appropriate.
  50. 50. Controversies • A conservative (but aggressive) approach would be to recommend radiation to all LABC patients • However, patients with little or no residual breast/axillary disease following neoadjuvant chemotherapy may not derive a significant benefit regional radiotherapy. • Existing data are limited.
  51. 51. Radiation • At least four metastatic lymph nodes or 5 cm of residual disease in the breast after chemotherapy clearly benefit from locoregional irradiation • All lumpectomy patients require breast irradiation • Post-Mastectomy • Pretreatment stage III or cT3 tumors • > or = 4 LN’s + • ? Pretreatment stage II disease with high risk features
  52. 52. Outline 1. Individual Patient 2. Anatomy: Target Volume Delineation Organs at Risk 3. Response Assessment and Adaptive Radiotherapy 4. Conclusion: Integration into treatment delivery 5. Questions
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×